Showing results (31-40 of 45) with videos related to
Sort By:
Pageof 5
Blood|November 4, 2006
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaJeffrey E Lancet, Ivana Gojo, Jason Gotlib, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2005
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemiaEric J Feldman, Joseph Brandwein, Richard Stone, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3Thomas Fischer, Richard M Stone, Daniel J Deangelo, et al.Blood|December 28, 2007
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemiaMitch Raponi, Jeffrey E Lancet, Hongtao Fan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2004
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial resultsJohn P Leonard, Morton Coleman, Jamie C Ketas, et al.Transfusion|August 6, 2025
Adding the FcRn antagonist efgartigimod for the prevention of IgG-mediated complications in the peri-transplant periodDennis L Cooper, Jhannine Alyssa Verceles, Taba Kheradmand, et al.Haematologica|July 17, 2025
Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemiaBradley Rockwell, Mendel Goldfinger, Ioannis Mantzaris, et al.Blood|February 7, 2025
Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b studyIoannis Mantzaris, Mendel Goldfinger, Matan Uriel, et al.Blood|September 26, 2007
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza, James A Reeves, Eric J Feldman, et al.Molecular Cancer Therapeutics|November 17, 2017
Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid LeukemiaFu Li, May Kung Sutherland, Changpu Yu, et al.Pageof 5